Journal of drug delivery最新文献

{"title":"PLGA Nanoparticles for Ultrasound-Mediated Gene Delivery to Solid Tumors.","authors":"Marxa Figueiredo,&nbsp;Rinat Esenaliev","doi":"10.1155/2012/767839","DOIUrl":"https://doi.org/10.1155/2012/767839","url":null,"abstract":"<p><p>This paper focuses on novel approaches in the field of nanotechnology-based carriers utilizing ultrasound stimuli as a means to spatially target gene delivery in vivo, using nanoparticles made with either poly(lactic-co-glycolic acid) (PLGA) or other polymers. We specifically discuss the potential for gene delivery by particles that are echogenic (amenable to destruction by ultrasound) composed either of polymers (PLGA, polystyrene) or other contrast agent materials (Optison, SonoVue microbubbles). The use of ultrasound is an efficient tool to further enhance gene delivery by PLGA or other echogenic particles in vivo. Echogenic PLGA nanoparticles are an attractive strategy for ultrasound-mediated gene delivery since this polymer is currently approved by the US Food and Drug Administration for drug delivery and diagnostics in cancer, cardiovascular disease, and also other applications such as vaccines and tissue engineering. This paper will review recent successes and the potential of applying PLGA nanoparticles for gene delivery, which include (a) echogenic PLGA used with ultrasound to enhance local gene delivery in tumors or muscle and (b) PLGA nanoparticles currently under development, which could benefit in the future from ultrasound-enhanced tumor targeted gene delivery.</p>","PeriodicalId":15575,"journal":{"name":"Journal of drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/767839","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30577309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanotechnology in medicine: from inception to market domination.","authors":"Valentina Morigi,&nbsp;Alessandro Tocchio,&nbsp;Carlo Bellavite Pellegrini,&nbsp;Jason H Sakamoto,&nbsp;Marco Arnone,&nbsp;Ennio Tasciotti","doi":"10.1155/2012/389485","DOIUrl":"https://doi.org/10.1155/2012/389485","url":null,"abstract":"<p><p>Born from the marriage of nanotechnology and medicine, nanomedicine is set to bring advantages in the fight against unmet diseases. The field is recognized as a global challenge, and countless worldwide research and business initiatives are in place to obtain a significant market position. However, nanomedicine belongs to those emerging sectors in which business development methods have not been established yet. Open issues include which type of business model best fits these companies and which strategies would lead them to sustained growth. This paper describes the financial and strategic decisions by nanomedicine start-ups to reach the market successfully, obtain a satisfactory market share, and build and maintain a competitive defendable advantage. Walking nanomedicine-product from the hands of the inventor to those of the doctor, we explored the technological transfer process, which connects laboratories or research institutions to the marketplace. The process involves detailed analysis to evaluate the potentials of end-products, and researches to identify market segment, size, structure, and competitors, to ponder a possible market entry and the market share that managers can realistically achieve at different time horizons. Attracting funds is crucial but challenging. However, investors are starting to visualize the potentials of this field, magnetized by the business of \"nano.\"</p>","PeriodicalId":15575,"journal":{"name":"Journal of drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/389485","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30576304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design and characterization of a silk-fibroin-based drug delivery platform using naproxen as a model drug.","authors":"Tatyana Dyakonov,&nbsp;Chue Hue Yang,&nbsp;Derek Bush,&nbsp;Saujanya Gosangari,&nbsp;Shingai Majuru,&nbsp;Aqeel Fatmi","doi":"10.1155/2012/490514","DOIUrl":"https://doi.org/10.1155/2012/490514","url":null,"abstract":"<p><p>The objective of this proof-of-concept study was to develop a platform for controlled drug delivery based on silk fibroin (SF) and to explore the feasibility of using SF in oral drug delivery. The SF-containing matrixes were prepared via spray-drying and film casting, and the release profile of the model drug naproxen sodium was evaluated. Attenuated total reflectance Fourier transform infrared spectroscopy (FTIR) has been used to observe conformational changes in SF- and drug-containing compositions. SF-based films, spray-dried microparticles, and matrixes loaded with naproxen were prepared. Both FTIR spectra and in vitro dissolution data demonstrated that SF β-sheet conformation regulates the release profile of naproxen. The controlled release characteristics of the SF-containing compositions were evaluated as a function of SF concentration, temperature, and exposure to dehydrating solvents. The results suggest that SF may be an attractive polymer for use in controlled drug delivery systems.</p>","PeriodicalId":15575,"journal":{"name":"Journal of drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/490514","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30576305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment.","authors":"Sana Abbasi,&nbsp;Arghya Paul,&nbsp;Wei Shao,&nbsp;Satya Prakash","doi":"10.1155/2012/686108","DOIUrl":"https://doi.org/10.1155/2012/686108","url":null,"abstract":"<p><p>Most anticancer drugs are greatly limited by the serious side effects that they cause. Doxorubicin (DOX) is an antineoplastic agent, commonly used against breast cancer. However, it may lead to irreversible cardiotoxicity, which could even result in congestive heart failure. In order to avoid these harmful side effects to the patients and to improve the therapeutic efficacy of doxorubicin, we developed DOX-loaded polyethylenimine- (PEI-) enhanced human serum albumin (HSA) nanoparticles. The formed nanoparticles were ~137 nm in size with a surface zeta potential of ~+15 mV, prepared using 20 μg of PEI added per mg of HSA. Cytotoxicity was not observed with empty PEI-enhanced HSA nanoparticles, formed with low-molecular weight (25 kDa) PEI, indicating biocompatibility and safety of the nanoparticle formulation. Under optimized transfection conditions, approximately 80% of cells were transfected with HSA nanoparticles containing tetramethylrhodamine-conjugated bovine serum albumin. Conclusively, PEI-enhanced HSA nanoparticles show potential for developing into an effective carrier for anticancer drugs.</p>","PeriodicalId":15575,"journal":{"name":"Journal of drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/686108","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30340602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translating nanotechnology from bench to pharmaceutical market: barriers, success, and promises.","authors":"Abhijit A Date,&nbsp;Rajesh R Patil,&nbsp;Riccardo Panicucci,&nbsp;Eliana B Souto,&nbsp;Robert W Lee","doi":"10.1155/2012/678910","DOIUrl":"https://doi.org/10.1155/2012/678910","url":null,"abstract":"Nanotechnology is a buzzword of this millennium and it has transformed the face of research in science and technology. The advent of nanotechnology has also influenced the biomedical and pharmaceutical research since last decade. Various nano-architectures have been designed for improving the therapeutic performance of drugs, proteins, peptides, and genes and to achieve their targeting at the site of action. Although nanotechnology has demonstrated dramatic potential in drug delivery research, like any technology, its real success depends on the ability of drug delivery scientists to translate and scale innovations to the commercial pharmaceutical products. It is indeed a very challenging task to successfully overcome manufacturing, clinical, and regulatory hurdles associated with a nanotech product. Nevertheless, the pharmaceutical industry has witnessed commercialization of the nanotechnology-based products for various applications. In the present special issue, we have tried to consolidate various aspects of existing and upcoming nanotechnologies for drug delivery. \u0000 \u0000Contribution by V. Morigi et al. takes an overview of business potential and market trend of pharmaceutical nanotechnology. The authors have also discussed financial aspects of nanotechnology by citing noteworthy examples of few nanotech products that have already been commercialized. This contribution could be useful to scientists aiming to start up nanotechnological business ventures. Contribution by N. Anton et al. demonstrates how nanotechnology can change the face of conventional drug delivery systems. In this interesting investigation, the authors demonstrate that coating of conventional tablets with lipid nanoemulsion can be used to modulate the release of the drug from tablet matrix. The paper by P. Severino et al. gives an account of potential of solid lipid nanocarriers for the oral delivery of drugs and peptides. The authors have provided information about the lipids that can be used for oral delivery, role of lipids in the oral delivery, toxicological aspects of lipid nanocarriers, and products under clinical development. \u0000 \u0000S. Banerjee et al. have given a complete overview of polyethylene-glycol- (PEG-) based conjugates for drug delivery. The contribution fosters understanding design aspects of and chemistry behind PEG-based nano-architectures for drug delivery. Furthermore, the paper has a detailed discussion on the various PEG-conjugates available in the pharmaceutical market. Contribution by A. Garcia et al. highlights the potential of particle replication in nonwetting templates (PRINT), a platform technology based on lithographic techniques for drug delivery applications. The contribution clearly demonstrates potential of PRINT technology to generate particles of various, but precise, morphology for a variety of drugs and biotechnology-based therapeutics (proteins and siRNA). The application of PRINT technology for generating aerosols for pulmonary applications ","PeriodicalId":15575,"journal":{"name":"Journal of drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/678910","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30735066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adsorption and desorption of bioactive proteins on hydroxyapatite for protein delivery systems.","authors":"Chie Kojima,&nbsp;Kenji Watanabe","doi":"10.1155/2012/932461","DOIUrl":"https://doi.org/10.1155/2012/932461","url":null,"abstract":"<p><p>Hydroxyapatite (HA) is a precursor of bone and has been studied as a biomaterial. We attempted HA to apply to protein delivery systems. In this study, the association and dissociation properties of two types of bioactive proteins, cytochrom c and insulin, to HA were investigated. Cytochrom c was less associated with HA than insulin, which was easily released from it. However, the release of insulin from HA was slow. Insulin was released from HA at pH 7.4 more rapidly than at pH 3. The association and dissociation properties might be influenced by the size, solubility and net charge of protein. HA is a potential protein carrier with controlled release.</p>","PeriodicalId":15575,"journal":{"name":"Journal of drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/932461","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30577310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipoplatin formulation review article.","authors":"G P Stathopoulos,&nbsp;T Boulikas","doi":"10.1155/2012/581363","DOIUrl":"https://doi.org/10.1155/2012/581363","url":null,"abstract":"<p><p>Patented platform technologies have been used for the liposomal encapsulation of cisplatin (Lipoplatin) into tumor-targeted 110 nm (in diameter) nanoparticles. The molecular mechanisms, preclinical and clinical data concerning lipoplatin, are reviewed here. Lipoplatin has been successfully administered in three randomized Phase II and III clinical trials. The clinical data mainly include non-small-cell lung cancer but also pancreatic, breast, and head and neck cancers. It is anticipated that lipoplatin will replace cisplatin as well as increase its potential applications. For the first time, a platinum drug has shown superiority to cisplatin, at least in non-squamous non-small-cell lung cancer as reported in a Phase III study which documented a simultaneous lowering of all of the side effects of cisplatin.</p>","PeriodicalId":15575,"journal":{"name":"Journal of drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/581363","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30131017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery.","authors":"Patrícia Severino,&nbsp;Tatiana Andreani,&nbsp;Ana Sofia Macedo,&nbsp;Joana F Fangueiro,&nbsp;Maria Helena A Santana,&nbsp;Amélia M Silva,&nbsp;Eliana B Souto","doi":"10.1155/2012/750891","DOIUrl":"https://doi.org/10.1155/2012/750891","url":null,"abstract":"<p><p>Lipids and lipid nanoparticles are extensively employed as oral-delivery systems for drugs and other active ingredients. These have been exploited for many features in the field of pharmaceutical technology. Lipids usually enhance drug absorption in the gastrointestinal tract (GIT), and when formulated as nanoparticles, these molecules improve mucosal adhesion due to small particle size and increasing their GIT residence time. In addition, lipid nanoparticles may also protect the loaded drugs from chemical and enzymatic degradation and gradually release drug molecules from the lipid matrix into blood, resulting in improved therapeutic profiles compared to free drug. Therefore, due to their physiological and biodegradable properties, lipid molecules may decrease adverse side effects and chronic toxicity of the drug-delivery systems when compared to other of polymeric nature. This paper highlights the importance of lipid nanoparticles to modify the release profile and the pharmacokinetic parameters of drugs when administrated through oral route.</p>","PeriodicalId":15575,"journal":{"name":"Journal of drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/750891","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30330666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Noble metal nanoparticles applications in cancer.","authors":"João Conde,&nbsp;Gonçalo Doria,&nbsp;Pedro Baptista","doi":"10.1155/2012/751075","DOIUrl":"https://doi.org/10.1155/2012/751075","url":null,"abstract":"<p><p>Nanotechnology has prompted new and improved materials for biomedical applications with particular emphasis in therapy and diagnostics. Special interest has been directed at providing enhanced molecular therapeutics for cancer, where conventional approaches do not effectively differentiate between cancerous and normal cells; that is, they lack specificity. This normally causes systemic toxicity and severe and adverse side effects with concomitant loss of quality of life. Because of their small size, nanoparticles can readily interact with biomolecules both at surface and inside cells, yielding better signals and target specificity for diagnostics and therapeutics. This way, a variety of nanoparticles with the possibility of diversified modification with biomolecules have been investigated for biomedical applications including their use in highly sensitive imaging assays, thermal ablation, and radiotherapy enhancement as well as drug and gene delivery and silencing. Here, we review the available noble metal nanoparticles for cancer therapy, with particular focus on those already being translated into clinical settings.</p>","PeriodicalId":15575,"journal":{"name":"Journal of drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/751075","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30214372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cyclodextrin-containing polymers: versatile platforms of drug delivery materials.","authors":"Jeremy D Heidel,&nbsp;Thomas Schluep","doi":"10.1155/2012/262731","DOIUrl":"https://doi.org/10.1155/2012/262731","url":null,"abstract":"<p><p>Nanoparticles are being widely explored as potential therapeutics for numerous applications in medicine and have been shown to significantly improve the circulation, biodistribution, efficacy, and safety profiles of multiple classes of drugs. One leading class of nanoparticles involves the use of linear, cyclodextrin-containing polymers (CDPs). As is discussed in this paper, CDPs can incorporate therapeutic payloads into nanoparticles via covalent attachment of prodrug/drug molecules to the polymer (the basis of the Cyclosert platform) or by noncovalent inclusion of cationic CDPs to anionic, nucleic acid payloads (the basis of the RONDEL platform). For each of these two approaches, we review the relevant molecular architecture and its rationale, discuss the physicochemical and biological properties of these nanoparticles, and detail the progress of leading drug candidates for each that have achieved clinical evaluation. Finally, we look ahead to potential future directions of investigation and product candidates based upon this technology.</p>","PeriodicalId":15575,"journal":{"name":"Journal of drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/262731","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30571333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}